AbCellera Biologics (ABCL) Return on Sales (2020 - 2026)

AbCellera Biologics has reported Return on Sales for 7 years, with the latest figure at 0.05% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales rose 6.0% year-over-year to 0.05%; the trailing twelve-month figure through Mar 2026 stood at 0.02% (up 5.0% YoY), and the FY2025 full-year result was 0.02%, up 4.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.05%, down from 0.0% in the prior quarter.
• The five-year high for Return on Sales was 0.01% in Q1 2022, with the low at 0.11% in Q1 2025.
• Historically, Return on Sales has averaged 0.04% across 5 years, with a median of 0.04% in 2024.
• The largest YoY upside for Return on Sales was 7 bps in 2025 against a maximum downside of 7 bps in 2025.
• AbCellera Biologics' Return on Sales stood at 0.01% in 2022, then plunged by 270 bps to 0.05% in 2023, then plunged by 32 bps to 0.07% in 2024, then surged by 97 bps to 0.0% in 2025, then tumbled by 2503 bps to 0.05% in 2026.
• The last three Return on Sales figures came in at 0.05% (Q1 2026), 0.0% (Q4 2025), and 0.06% (Q3 2025), per Business Quant data.